Highlights from Studies Presented at the American Heart Association Scientific Session 2020: Navigating New Roads in Prevention
Author:
Funder
U.S. Department of Veterans Affairs
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine
Link
http://link.springer.com/content/pdf/10.1007/s11883-020-00900-5.pdf
Reference31 articles.
1. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, et al. Cardiac myosin activation with Omecamtiv Mecarbil in systolic heart failure. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2025797Randomized controlled trial showing that the primary outcome of cardiovascular death or heart failure was significantly reduced among patients with heart failure with reduced ejection fraction, New York Heart Association (NYHA) functional class II-IV and LVEF ≤35% receiving omecamtiv mecarbil compared to placebo.
2. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2030183In patients with a recent admission with HF and previous diagnosis of T2DM, sotagliflozin, when compared to placebo, significantly reduced rate of primary endpoint (cardiovascular mortality, HF hospitalizations).
3. Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020. https://doi.org/10.1001/jama.2020.22258In a multi-centric, double-blinded, randomized, placebo-controlled trial of 13,078 patients with either established ASCVD, diabetes or or high-risk primary prevention patients on maximally tolerated statin therapy, use of of omega-3 CA failed to show significant reduction in cardiovascular events among patients with use compared with corn oil.
4. Kalstad AA, Myhre PL, Laake K, Tveit SH, Schmidt EB, Smith P, et al. Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction. Circulation. 2020. https://doi.org/10.1161/CIRCULATIONAHA.120.052209.
5. Rosenson RS, Burgess LJ, Ebenbichler CF, Baum SJ, Stroes ESG, Ali S, Khilla N, Hamlin R, Pordy R, Dong Y, Son V, Gaudet D. Evinacumab in Patients with Refractory Hypercholesterolemia. N Engl J Med. 2020 Dec 10;383(24):2307–19. https://doi.org/10.1056/NEJMoa2031049.
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. New therapeutic options for patients with heart failure with reduced ejection fraction and acute decompensated heart failure;Advances in Medical Sciences;2022-03
2. Highlights of Cardiovascular Disease Studies Presented at the 2021 American Heart Association Scientific Sessions;Current Atherosclerosis Reports;2022-01
3. Highlights of Cardiovascular Disease Studies Presented at the 2021 European Society of Cardiology Congress;Current Atherosclerosis Reports;2021-10-14
4. PUFA Supplementation and Heart Failure: Effects on Fibrosis and Cardiac Remodeling;Nutrients;2021-08-26
5. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease risk: current status and treatments;Current Opinion in Endocrinology, Diabetes & Obesity;2021-01-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3